Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 35
Treatment-assignment count: 0
Stratification count: 0
breast cancer · Therapy Not Normalized
RET fusion is flagged as manual review required because public trials show inclusion required evidence in 54 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 35
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 2
Common snippets: HER2-low | HER2-low
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT05012397 | https://clinicaltrials.gov/study/NCT03459781 | https://clinicaltrials.gov/study/NCT06700070 | https://clinicaltrials.gov/study/NCT02299635 | https://clinicaltrials.gov/study/NCT01212887 | https://clinicaltrials.gov/study/NCT06273852 | https://clinicaltrials.gov/study/NCT04874935 | https://clinicaltrials.gov/study/NCT00940498 | https://clinicaltrials.gov/study/NCT01846091 | https://clinicaltrials.gov/study/NCT06556108 | https://clinicaltrials.gov/study/NCT03499353 | https://clinicaltrials.gov/study/NCT03065621 | https://clinicaltrials.gov/study/NCT03206203 | https://clinicaltrials.gov/study/NCT04214288 | https://clinicaltrials.gov/study/NCT00834678 | https://clinicaltrials.gov/study/NCT00003953 | https://clinicaltrials.gov/study/NCT03637868 | https://clinicaltrials.gov/study/NCT00651976 | https://clinicaltrials.gov/study/NCT03696030 | https://clinicaltrials.gov/study/NCT01234532 | https://clinicaltrials.gov/study/NCT00058526 | https://clinicaltrials.gov/study/NCT04142554 | https://clinicaltrials.gov/study/NCT03747042 | https://clinicaltrials.gov/study/NCT01565499 | https://clinicaltrials.gov/study/NCT00070057 | https://clinicaltrials.gov/study/NCT00754312 | https://clinicaltrials.gov/study/NCT00616967 | https://clinicaltrials.gov/study/NCT05461768 | https://clinicaltrials.gov/study/NCT02850302 | https://clinicaltrials.gov/study/NCT05982093 | https://clinicaltrials.gov/study/NCT02531425 | https://clinicaltrials.gov/study/NCT00544804 | https://clinicaltrials.gov/study/NCT05364255 | https://clinicaltrials.gov/study/NCT05244434 | https://clinicaltrials.gov/study/NCT03058939 | https://clinicaltrials.gov/study/NCT07178938 | https://clinicaltrials.gov/study/NCT02398773 | https://clinicaltrials.gov/study/NCT04852887 | https://clinicaltrials.gov/study/NCT05452213 | https://clinicaltrials.gov/study/NCT00256217 | https://clinicaltrials.gov/study/NCT02694809 | https://clinicaltrials.gov/study/NCT05333874 | https://clinicaltrials.gov/study/NCT07067138 | https://clinicaltrials.gov/study/NCT01898117 | https://clinicaltrials.gov/study/NCT02221999 | https://clinicaltrials.gov/study/NCT04770272 | https://clinicaltrials.gov/study/NCT05812326 | https://clinicaltrials.gov/study/NCT03606967 | https://clinicaltrials.gov/study/NCT04741204 | https://clinicaltrials.gov/study/NCT06547840 | https://clinicaltrials.gov/study/NCT03045393 | https://clinicaltrials.gov/study/NCT02593227 | https://clinicaltrials.gov/study/NCT03106077 | https://clinicaltrials.gov/study/NCT03012100